(Q34612118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

review article

1 reference

title

Cytochrome P450 polymorphisms and response to antipsychotic therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

Maria Gabriella Scordo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 March 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

201-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

Enzymatic oxidation of xenobiotic chemicals

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

The metabolism of atypical antipsychotic drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Human cytochromes P450: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

21 January 2018

Metabolic polymorphisms

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Thioridazine cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Drug metabolism and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Extrapyramidal symptoms after addition of fluvoxamine to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Influence of patient-related variables on clozapine plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Erythromycin-induced clozapine toxic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Biotransformation of Post-Clozapine Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Interaction of olanzapine with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Quetiapine: a review of its safety in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Pharmacogenetics of classical and new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.2.201

21 January 2018

Identifiers

DOI

10.1517/14622416.3.2.201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11972442%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference